Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1DNA Repair-Deficiency Disorders 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × omega-N-Methylarginine × Clear all
NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡